Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT Study: Sequential Omalizumab After Other Biologics in Severe Asthma
jRCTs031240091Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of omalizumab in severe asthma and asthma, sponsored by Novartis. Primary endpoint: Primary: Proportion of patients achieving a partial response at 24 weeks after switch to omalizumab. Started Jul 2024; status: active, not recruiting.
02
Drugs
omalizumab
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on jRCTs031240091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240091.